Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months

Data Readoutpositivebemnifosbuvir/ruzasvir (BEM/RZR)EpclusaPositive

AI Analysis

Summary

Atea Pharmaceuticals announced that its hepatitis C combination therapy bemnifosbuvir/ruzasvir achieved non-inferiority compared to Gilead's Epclusa. AbCellera secured its second partnership deal in two months.

Outcome Details

BEM/RZR combination therapy hit non-inferiority against Epclusa, a standard of care for hepatitis C

Importance:6/10

Sentiment:

0.70

hepatitis Ccombination therapynon-inferiorityclinical dataantiviral

Related Companies

$AVIR $GILD

Read the original article

Published by Endpoints News on July 29, 2026 3:17 PM

Read Original